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Introduction
PFAPA syndrome (acronym for periodic fever, aphthous
stomatitis, pharyngitis and cervical adenitis) is the most
common cause of periodic fever in childhood. It is consid-
ered part of the wide family of the autoinflammatory dis-
eases, but a genetic or molecular marker hasn’t been
identified yet, therefore, its etiology is still unknown. Diag-
nosis is essentially based on clinical criteria but, especially
in younger children, it is sometimes difficult to differenti-
ate it from other hereditary periodic fever syndromes.
Familial (Mediterranean) fever (FMF) is caused by MEFV
gene mutations, mostly inherited in autosomal recessive
fashion. Yet, there are reports of heterozygous MEFV
mutation carriers with clinical features of FMF.
Objectives
To assess the effects of heterozygous MEFV mutations on
the clinical features of PFAPA syndrome.
Methods
We studied 27 patients with typical clinical manifestations
of PFAPA syndrome, ages 2 -12 years (mean age
9.56 years). Direct sequencing of MEFV gene was per-
formed, 21 patient had no mutations, and 6 patients had
various heterozygous mutations of MEFV. We analyzed
the spectrum of clinical features, response to prednisone
treatment and tonsillectomy in patients who carried
MEFV mutations in the heterozygous state and patients
without mutations.
Results
In comparison with PFAPA group without MEFV muta-
tion patients with heterozygous mutations in MEFV gene
had the following features: the symptoms begin at a
somewhat younger age (15.7 months versus 19 months),
the duration of attacks was shorter (3.92 days vs 5,1 days)
and the interval between the attacks of the disease was
found to be shorter, these patients rarely has had arthral-
gias, hepatosplenomegaly and aphthous stomatitis was
present less frequently, during the attack CRP levels were
higher, yet (unlike HPF) they always normalized between
the attacks. In the group of carriers of heterozygous
MEFV mutations all patients responded to steroid treat-
ment and had full effect after tonsillectomy.
Conclusion
In opposite to some other reports in our PFAPA group,
patients with heterozygous MEFV mutation had typical
PFAPA symptoms and no features suspicious of FMF.
Thus, the pathologic meaning of the MEFV mutation in
these group is not clear and does not seem to influence
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